-Reuters Citing IFAX
Kineta To Present New Preclinical Data On Lead Anti-CD27 Agonist Antibody At AACR Special Conference On Tumor Immunology And Immunotherapy
Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the